News

Enzymlogic receives the seal of innovative SME

 Apr, 15th  2016

The award identifies companies that have proven their innovative spirit in recent years and acknowledges the critical role of excellent science and industrial leadership play in solving societal challenges.


Enzymlogic Kinase and GPCR drug discovery services RECIEVES THE SEAL OF INNOVATIVE SME

Drug discovery innovator, Enzymlogic, was awarded the Seal of Innovative SME from the Spanish Ministry of Economy and Competitiveness for the effectiveness and potential of its binding kinetics technology platform.

Enzymlogic’s binding kinetics platform went through a competitive evaluation process to receive the seal of Innovative SME, a distinction only awarded to businesses that stand out for their innovative character and for having obtained public funding through competitive calls for technology-driven proposals.


At Enzymlogic, we firmly believe that pushing back the frontiers of knowledge means discovering new ways to create solutions that are truly different and surprising. Innovation is the driving force that enables us to stay one-step ahead and bring groundbreaking solutions to the pharmaceutical and biotech industries in order to assist in the discovery life-changing drugs capable of tackling the medical challenges of our times.



About Enzymlogic

Enzymlogic offers in vitro biochemical and cell-based assays to the biotechnological and pharmaceutical companies, life science laboratories and academic groups. Our binding kinetics, kinetic selectivity, assay development, profiling and screening services enable faster and cost-effective drug discovery by identifying the most promising drug candidates as well as withdrawing those compounds likely to fail in pre-clinical development. Additionally, Enzymlogic’s pioneering approach provides predictive tools that deliver physiologically relevant insights earlier in the drug discovery process.

Back